Last reviewed · How we verify
SPD422
At a glance
| Generic name | SPD422 |
|---|---|
| Also known as | Anagrelide hydrochloride |
| Sponsor | Shire |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants (PHASE1)
- Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia (PHASE3)
- Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPD422 CI brief — competitive landscape report
- SPD422 updates RSS · CI watch RSS
- Shire portfolio CI